Related coverage linked through entity extraction aliases.
Aug 18, 2026
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
Aug 17, 2026
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Aug 14, 2026
FDA approved iberdomide (Zenbexus) with daratumumab and dexamethasone for pretreated myeloma. The EXCALIBER-RRMM trial showed a 41% MRD-negative complete response rate vs 21%.
Aug 14, 2026
Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
Aug 12, 2026
Perspective Therapeutics plans May 2026 analyst event, Q1 results, and conference appearances. The radiopharmaceutical firm is advancing 212Pb-based therapies in Phase 1/2a trials and expanding facilities.
Aug 11, 2026
First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
Aug 10, 2026
Flow-based human tissue models show stronger T-cell activity than static cultures, with blinatumomab inducing significant B-cell killing and cytokine release. Sartorius has introduced a 96-well multi-organ tox plate for drug toxicity testing, while in vitro systems are increasingly used as new approach methodologies to complement animal models.
Aug 02, 2026
Recent studies show microbiome modulation boosts chemotherapy accumulation, peptide-based mRNA vaccines shrink neuroblastoma tumors by 70%, and engineered LNPs enhance lymph node delivery while cutting side effects.
Jul 26, 2026
CaroMont Health is investing $200 million to expand cancer care, including a new Gastonia cancer center that will double oncology capacity to 3,000 patients per year. The center is planned to open in Fall 2028.
Jul 29, 2026
A review and two studies report advances in nanomaterial-based cancer immunotherapy, including engineered nanoparticles that boost immunogenic tumor cell death, nanosheet artificial antibodies that block PD-L1, and design principles for overcoming delivery barriers. These approaches aim to improve immune activation and reduce off-target effects.
Jul 01, 2026
The UK's £1.6bn national AI strategy targets healthcare breakthroughs from cancer detection to drug discovery. The AI healthcare market is forecast to reach US$696bn by 2034, a 38.5% CAGR.
Jun 21, 2026
A 2025 systematic review of 561,850 refugees reveals substantial cancer burden variation and barriers to care. Advanced-stage diagnosis is common, and UNHCR funding gaps in Jordan highlight resource limits.
Aug 08, 2026
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
Aug 07, 2026
Biotechnology is now a national security issue in Washington, with investment restrictions, export controls, and procurement bans targeting China. The Pentagon designated WuXi AppTec as a Chinese military company, sparking a legal challenge. Policymakers also warn about supply chain dependence, biosecurity, and the dual-use dilemma.
Jul 15, 2026
Researchers at MD Anderson developed an extracellular vesicle-based platform that delivers full-length DMD mRNA, restoring dystrophin production and improving muscle function in preclinical Duchenne muscular dystrophy models. The study, published in Nature Biomedical Engineering, showed reduced side effects compared with viral gene therapies.
Jul 28, 2026
More than 80% of U.S. physicians use AI in their work. AI is revealing new cardiac biomarkers and speeding drug discovery, with the healthcare AI market projected to reach $505.6 billion by 2033—but studies warn of bias and eroding critical thinking.
Jul 23, 2026
NEOK Bio dosed first patients in Phase 1 trials of lead bispecific ADCs NEOK001 and NEOK002 for advanced solid tumors. The candidates target B7-H3/ROR1 and EGFR/MUC1, with initial data expected in 2027.
Aug 09, 2026
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Aug 09, 2026
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
Mar 14, 2026
Ultrasound-activated bubbles show promise for cancer therapy. Duke's SonoPIN killed 50% of cancer cells, while Case Western nanobubbles broke down tumor barriers, enabling potential trials in two years.
